ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA
    5.
    发明申请
    ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA 审中-公开
    抗感染药物和疫苗

    公开(公告)号:US20090208531A1

    公开(公告)日:2009-08-20

    申请号:US12279332

    申请日:2007-02-16

    摘要: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.

    摘要翻译: 这些疫苗靶向H5N1,H1,H3和其他亚型亚型,旨在引发中和抗体以及细胞免疫。 DNA疫苗表达来自流感的血凝素(HA)或核蛋白(NP)蛋白,其密码子优化和/或含有影响蛋白质正常功能的HA蛋白酶切割位点的修饰。 表达相同插入片段的腺病毒构建体已被设计用于主要的增强策略。 已经开发了基于使用具有或不具有切割位点的折叠三聚稳定结构域的昆虫或哺乳动物细胞的基于蛋白质产生的蛋白质疫苗,以有助于这种蛋白质的纯化。 本发明的另一个实施方案是具有HA假型慢病毒载体的工作,其将用于筛选患者中的中和抗体并筛选诊断和治疗性抗病毒剂,例如单克隆抗体。